Patents by Inventor David Charles Jackson
David Charles Jackson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11947066Abstract: A drill hole logging system (5) incorporates a computing system (58) at the surface and a deployment mechanism (40) for conveying a logging tool (10) configured to measure one or more geophysical parameters into a drill hole (20). A transmission means (57) communicates commands and data representing the geophysical parameters between the surface computing system and the logging tool. A borehole caliper (300) is employed to profile the inside of the borehole.Type: GrantFiled: December 1, 2020Date of Patent: April 2, 2024Assignee: REFLEX INSTRUMENTS ASIA PACIFIC PTY LTDInventors: David Charles Lawie, Christopher Thomas Koplan, John Carl Jackson, Cory Bryce Wilson, Joel Hitchen, Christopher Pell, Frederick Blaine, Erik Gutterud
-
Publication number: 20240050364Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: October 10, 2023Publication date: February 15, 2024Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Patent number: 11786458Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: May 24, 2022Date of Patent: October 17, 2023Assignee: ENA RESPIRATORY PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Publication number: 20230244091Abstract: Methods and devices to identify contact lens wearers predisposed to contact lens discomfort are described. The methods and devices involve obtaining a tear film sample from a person and determining an amount of interleukin-17A present in the tear film sample.Type: ApplicationFiled: February 27, 2023Publication date: August 3, 2023Applicants: CooperVision International Limited, The University of MelbourneInventors: Laura Elizabeth Downie, David Charles Jackson, Algis Jonas Vingrys, Nancy J. Keir, Inna Maltseva
-
Patent number: 11619832Abstract: Methods and devices to identify contact lens wearers predisposed to contact lens discomfort are described. The methods and devices involve obtaining a tear film sample from a person and determining an amount of interleukin-17A present in the tear film sample.Type: GrantFiled: February 27, 2019Date of Patent: April 4, 2023Assignees: COOPERVISION INTERNATIONAL LIMITED, THE UNIVERSITY OF MELBOURNEInventors: Laura Elizabeth Downie, David Charles Jackson, Algis Jonas Vingrys, Nancy J. Keir, Inna Maltseva
-
Publication number: 20220296505Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: May 24, 2022Publication date: September 22, 2022Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Patent number: 11351114Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: July 26, 2019Date of Patent: June 7, 2022Assignee: ENA THERAPEUTICS PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Publication number: 20190380952Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: July 26, 2019Publication date: December 19, 2019Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Publication number: 20190278105Abstract: Methods and devices to identify contact lens wearers predisposed to contact lens discomfort are described. The methods and devices involve obtaining a tear film sample from a person and determining an amount of interleukin-17A present in the tear film sample.Type: ApplicationFiled: February 27, 2019Publication date: September 12, 2019Applicants: CooperVision International Holding Company, LP, The University of MelbourneInventors: Laura Elizabeth Downie, David Charles Jackson, Algis Jonas Vingrys, Nancy J. Keir, Inna Maltseva
-
Patent number: 10406100Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: May 16, 2017Date of Patent: September 10, 2019Assignee: ENA THERAPEUTICS PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Patent number: 9889195Abstract: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.Type: GrantFiled: January 22, 2015Date of Patent: February 13, 2018Assignee: INNAVAC PTY LTDInventors: David Charles Jackson, Weiguang Zeng, Brendon Yew Loong Chua
-
Publication number: 20170274068Abstract: The present invention provides an immunogenic composition comprising a charged antigen electrostatically associated with a Toll-Like Receptor (TLR) targeting moiety. The TLR targeting moiety comprises a TLR-2 agonist covalently attached to polyethylene glycol and to a hyper-branched charged peptide.Type: ApplicationFiled: September 11, 2015Publication date: September 28, 2017Inventors: DAVID CHARLES JACKSON, BRENDON YEW LOONG CHUA, TOSHIKI SEKIYA
-
Publication number: 20170246312Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: May 16, 2017Publication date: August 31, 2017Inventors: DAVID CHARLES JACKSON, AMABEL TAN, WEIGUANG ZENG
-
Patent number: 9676819Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: GrantFiled: September 22, 2011Date of Patent: June 13, 2017Assignee: INNAVAC PTY LTDInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Patent number: 9089508Abstract: The present invention relates to the targeted delivery of molecules to cells expressing toll-like receptors (TLRs). Aspects of the invention provide compounds comprising a positively charged group linked to a TLR ligand. These compounds are useful for in vitro and in vivo methods of transfection of TLR-expressing cells. Other aspects of the invention relate to the use of such compounds for repression of gene expression and DNA vaccination approaches.Type: GrantFiled: October 9, 2008Date of Patent: July 28, 2015Assignee: The University of MelbourneInventors: David Charles Jackson, Weiguang Zeng, Brendon Yew Loong Chua
-
Publication number: 20150150966Abstract: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.Type: ApplicationFiled: January 22, 2015Publication date: June 4, 2015Inventors: DAVID CHARLES JACKSON, WEIGUANG ZENG, BRENDON YEW LOONG CHUA
-
Patent number: 8945551Abstract: The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein; a biocompatible phosphate and/or sulphonamide compound; a biologically active agent; an aqueous insoluble alkaline earth metal phosphate; and a biocompatible glycan and/or proteoglycan.Type: GrantFiled: July 9, 2010Date of Patent: February 3, 2015Assignee: Polymers CRC Ltd.Inventors: David Edward Mainwaring, Mohammad Al Kobaisi, Brendon Yew Loong Chua, David Charles Jackson
-
Publication number: 20130230544Abstract: This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a TLR2 moiety in solution, wherein the TLR2 moiety comprises a TLR2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the TLR2 moiety.Type: ApplicationFiled: September 22, 2011Publication date: September 5, 2013Applicant: THE UNIVERSITY OF MELBOURNEInventors: David Charles Jackson, Amabel Tan, Weiguang Zeng
-
Publication number: 20120251536Abstract: The invention relates to biopolymer-gel based depot systems for prolonged and/or controlled release delivery of biologically active agents, methods for the manufacture of the biopolymer based gel-depots which include a biologically active agent, and uses of such biopolymer gel-depots in therapy. The biopolymer-gel based depot systems comprise a biocompatible polyaminosaccharide and/or protein; a biocompatible phosphate and/or sulphonamide compound; a biologically active agent; an aqueous insoluble alkaline earth metal phosphate; and a biocompatible glycan and/or proteoglycan.Type: ApplicationFiled: July 9, 2010Publication date: October 4, 2012Applicant: POLYMERS CRC LIMITEDInventors: David Edward Mainwaring, Mohammad Al Kobaisi, Brendon Yew Loong Chua, David Charles Jackson, Weiguang Zeng
-
Publication number: 20120064109Abstract: The present invention provides an immunogenic composition comprising an antigen and a dendritic cell targeting component. A charged group is covalently attached to a dendritic cell ligand and is electrostatically associated with the dendritic cell targeting component.Type: ApplicationFiled: October 7, 2011Publication date: March 15, 2012Applicant: THE UNIVERSITY OF MELBOURNEInventors: David Charles Jackson, Weiguang Zeng, Brendon Yew Loong Chua